Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Core Insights - Genmab A/S announced updated results from two clinical trials evaluating epcoritamab-bysp for treating diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), showing high overall response rates (ORR) and promising survival outcomes [2][8][11]. Trial Results Summary - In the EPCORE NHL-2 trial, Arm 8 demonstrated an ORR of 93% and a complete response (CR) rate of 86% in elderly patients with newly diagnosed DLBCL, with 79% of responders maintaining their response at two years [4][6]. - Arm 1 of the same trial showed an ORR of 98% and an 85% CR rate in patients with newly diagnosed DLBCL, with 74% of CRs ongoing after a median follow-up of 44.2 months [7][9]. - The EPCORE DLBCL-3 trial reported a 73% ORR and 62% CR rate in elderly patients unable to receive standard chemotherapy, with 54% progression-free and 65% alive at one year [3][14]. Safety Profile - Treatment-emergent adverse events (TEAEs) were consistent with previous studies, with Grade ≥3 infections occurring in 32% of patients, primarily in the first six cycles [5][10]. - Serious TEAEs included Grade 5 events, but no new serious infections were reported post-treatment [10][15]. Epcoritamab Overview - Epcoritamab is a bispecific antibody designed to engage T-cells and target B-cells, showing potential as a core therapy for various B-cell malignancies [23][24]. - The drug has received regulatory approval in certain lymphoma indications and is co-developed by Genmab and AbbVie [24][25]. Industry Context - DLBCL is the most common type of non-Hodgkin lymphoma, accounting for 25-30% of cases, with approximately 25,000 new cases diagnosed annually in the U.S. [17]. - Follicular lymphoma, accounting for 20-30% of NHL cases, is considered incurable with current therapies, highlighting the need for effective treatment options [18].